Selecting Patients for Treatment with 90Y Ibritumomab Tiuxetan (Zevalin)

Seminars in Oncology

Volumn 30, Issue 6 SUPPL. 17, 2003, Pages 17-22

  Gregory, Stephanie A ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FOLINIC ACID; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MESNA; METHOTREXATE; PREDNISONE; RADIOIMMUNOTHERAPEUTIC AGENT; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

B CELL LYMPHOMA; B CELL NONHODGKIN LYMPHOMA; BLOOD COMPONENT THERAPY; BLOOD TOXICITY; BONE MARROW DISEASE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; NONHODGKIN LYMPHOMA; PATIENT SELECTION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RETREATMENT; REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION;

EID: 0347359220     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.10.004     Document Type: Article

References (15)

1. Zevalin (ibritumomab tiuxetan) prescribing information: Cambridge, MA, Biogen Idec Inc, 2002
2. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
3. Hiddemann W, Longo DL, Coiffier B, et al: Lymphoma classification: The gap between biology and clinical management is closing. Blood 88:4085-4089, 1996
4. Wiseman GA, Gordon LI, Multani PS, et al: Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial. Blood 99:4336-4342, 2002
5. Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002
6. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463, 2002
7. Witzig TE, White CA, Gordon LI, et al: Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma. J Clin Oncol 21:1263-1270, 2003
8. Emmanouilides C, Witzig TE, Molina A, et al: Improved safety and efficacy of yttrium-90 ibritumomab tiuxetan radioimmunotherapy when administered as 2nd or 3rd line therapy for relapsed low-grade, follicular and transformed B-cell non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 22: 595, 2003 (abstr)
9. Ansell SM, Ristow KM, Habermann TM, et al: Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol 20:3885-3890, 2002
10. 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy does not preclude effective delivery of subsequent therapy for lymphoma. Proc Am Soc Clin Oncol 21:267a, 2002 (abstr)
11. Saleh F, Saleh M, Witzig T, et al: Rituximab administration subsequent to ibritumomab tiuxetan (Zevalin) radioimmunotherapy. Proc Am Soc Clin Oncol 21:8a, 2002 (abstr)
12. Gordon L, Witzig T, Schilder R, et al: High-dose therapy can be safely and successfully administered after Zevalin treatment. Proc Am Soc Clin Oncol 20:232b, 2001 (abstr)
13. Potamianos S, Varvarigou AD, Archimandritis SC: Radioimmunoscintigraphy and radioimmunotherapy in cancer: Principles and application. Anticancer Res 20:925-948, 2000
14. Wiseman GA, Colgan JP, Micallef INM, et al: Interim safety results of a phase I trial of two sequential doses of yttrium-90 ibritumomab tiuxetan for previously treated patients with low-grade non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 22:575, 2003 (abstr 2312)
15. Vose JM, Bierman PJ, Lynch JC, et al: Radioimmunotherapy with Bexxar combined with high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell transplantation (ASCT) for refractory non-Hodgkin's lymphoma (NHL): Synergistic results with no added toxicity. Proc Am Soc Clin Oncol 20:6a, 2001 (abstr)